메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

XtalPi Holdings Announces 2025 Interim Results

SHENZHEN, China, Aug. 27, 2025 -- Key Highlights from the Financial Report: Revenue surged 404% year over year to RMB 517 million in the first half of 2025. Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. XtalPi was added to the MSCI China Small Cap Index, underscoring strong recognition of its investment value by the international capital markets. Significant breakthroughs and milestones were achieved across multiple business lines. Drug Discovery Solutions: The Deep Integration of Ad
- 황정호 기자
- 2025-08-27 22:23
Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hits, has transformed drug discovery. HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 – featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.0 comes in a convenient kit format that is accessible to scientists in industry and
- 김갑성 기자
- 2025-08-27 21:30
Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval

SHENYANG, China, Aug. 27, 2025 -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector. Photon-counting CT (PCCT) is considered a breakthrough in next‑generation imaging. Unlike conventional CT scanners, which first convert X‑rays into light before generating digital images, the NeuViz P10 uses a cadmium zinc telluride (CZT) detector t
- 김갑성 기자
- 2025-08-27 21:03
NUHS SPEARHEADS AI-POWERED BRAIN CARE PROGRAMME TO TACKLE UNDERDIAGNOSIS AND IMPROVE PREVENTION OF DEMENTIA

Novel initiative in Asia integrates predictive AI with personalised health coaching to empower early action and prevention SINGAPORE, Aug. 27, 2025 -- Dementia remains a hidden epidemic in Singapore, with slightly more than half of all cases going undiagnosed. According to the Well-being of the Singapore Elderly (WiSE) 2023[1] study, 51.5 per cent of dementia cases remain undetected. This is a troubling figure given that an estimated 45 per cent of dementia cases are preventable through early lifestyle interventions[2]. In an effort to close this gap, a multidisc
- 김갑성 기자
- 2025-08-27 21:00
NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia's earnings

NEW YORK, Aug. 27, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia’s earnings Ashley Mastronardi delivers the pre-market update on August 27th Equities are up this morning as investors wait for chip giant Nvidia's Q2 earnings report. The company is set to release the earnings after market close this afternoon. As the most heavily weig
- 황정호 기자
- 2025-08-27 20:55
Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion

HONG KONG, Aug. 27, 2025 -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended 30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leveraged its strong capabilities in innovation and globalization to drive steady business development. During the Reporting Period, the Group's total revenue reached RMB87.28 billion, industrial operation profit amounted to RMB3.15 billion, and profit attributable to owners of the parent reached RMB661.2 million.
- 황정호 기자
- 2025-08-27 20:40
Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states

Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.
- 김갑성 기자
- 2025-08-27 20:00
Innovent Announces 2025 Interim Results and Business Updates

[ 메디채널 김갑성 기자 ] Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu, Found
- 김갑성 기자
- 2025-08-27 18:08
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

CHENGDU, China, Aug. 27, 2025 -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core product, Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®. The drug generated net sales of approximately RMB 170 million. Keymed strengthened its balance sheet with a successful placement raising ~HK$864 million, providing ample funds for pipeline development and commercialization.
- 김갑성 기자
- 2025-08-27 14:02
Digital twin technology with AI to boost efficiency and reliability in pharmaceutical manufacturing

Cambridge Advanced Research and Education in Singapore (CARES), the University of Cambridge's first overseas research centre, together with the A*STAR Institute for Infocomm Research (A*STAR I2R) has developed a digital twin platform that uses artificial intelligence (AI) and real-time plant data to enhance fault detection, system monitoring, and predictive maintenance in pharmaceutical manufacturing. The technology will be commercialised through Chemical Data Intelligence, a CARES spin-off, and will be made available to the Pharma Innovation Programme Singapore (PIPS) Consortium.
- 김갑성 기자
- 2025-08-27 13:00

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 09시 20분